- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Notice of annual general meeting in Biosergen AB | 2 | Cision News | ||
| 10.04. | Biosergen AB receives observation status | 277 | GlobeNewswire | On April 4, 2026, Biosergen AB ("the Company") disclosed that the Company's board of directors had resolved to pause the development of BSG005 and that the board of directors is exploring the possibility... ► Artikel lesen | |
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 04.04. | BIOSERGEN AB: Biosergen Pauses Development of BSG005 | 3 | Cision News | ||
| 10.02. | Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025 | 253 | GlobeNewswire (Europe) | February 10, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 01.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 680 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 28.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.11.2025 | 1.232 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.11.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.11.2025ISIN NameCA38940L2057 GRAYCLIFF... ► Artikel lesen | |
| 28.11.25 | XFRA ISIN CHANGE | 542 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA60283T2074 Mineral Hill Industries Ltd. 28.11.2025 CA38077F1045 Gold Strategy Inc. 01.12.2025 Tausch 1:1US60855D3098 Moleculin... ► Artikel lesen | |
| 28.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2025 | 515 | Xetra Newsboard | Das Instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2025 und ex Kapitalmassnahme am 01.12.2025 The instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY is traded... ► Artikel lesen | |
| 27.11.25 | Reverse split and Change of ISIN for Biosergen AB | 372 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Dec 1, 2025. The order book will not change.
Short... ► Artikel lesen | |
| 20.11.25 | Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen | 252 | GlobeNewswire (Europe) | STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB ("Biosergen" or the "Company") on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred... ► Artikel lesen | |
| 19.11.25 | Biosergen AB: Biosergen publishes interim report for the third quarter 2025 | 239 | GlobeNewswire (Europe) | November 19, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 20.08.25 | Biosergen AB: Biosergen publishes its interim report for the second quarter 2025 | 247 | GlobeNewswire (Europe) | Wednesday August 20, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on... ► Artikel lesen | |
| 24.07.25 | Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer | 307 | GlobeNewswire (Europe) | Stockholm, Sweden - July 24, 2025 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 29,820 | +3,97 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,080 | 0,00 % | Summit Therapeutics withdraws proposed securities offering citing market conditions | ||
| QIAGEN | 32,070 | -0,60 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| PROPANC BIOPHARMA | 2,430 | 0,00 % | Morning Market Movers: Galaxy Payroll, Propanc Biopharma, Big Tree Cloud, VS MEDIA See Big Swings | REDWOOD SHORES (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 40,340 | +11,71 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components | 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort
67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients... ► Artikel lesen | |
| CG ONCOLOGY | 57,64 | +4,95 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,150 | +3,62 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,240 | 0,00 % | Relay Therapeutics, Inc. - 8-K, Current Report | ||
| PARABILIS MEDICINES | 30,310 | -4,08 % | HBM Healthcare Investments AG: HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
11.06.2026 / 07:00... ► Artikel lesen | |
| ERASCA | 14,020 | +4,55 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,610 | +1,97 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| MBX BIOSCIENCES | 37,260 | +24,74 % | MBX Biosciences, Inc. - 8-K, Current Report | ||
| ADIAL PHARMACEUTICALS | 3,000 | 0,00 % | Adial Pharmaceuticals, Inc.: Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing | - Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,590 | +5,85 % | Arcutis Biotherapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 23,940 | -0,99 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) |
Das Unternehmen BIOSERGEN AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,675 Euro und damit -3,57 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.